Figure 4.

Chronic, intermittent WIN 55,212‐2 administration induces localized increases and decreases in local cerebral glucose utilization. Panel (a) – Chronic, intermittent WIN 55,212‐2 administration induced significantly decreased cerebral metabolism in the dorsal subiculum (DS), Mediodorsal thalamus (MD) and Habenula (Hab) and increased metabolism in the Globus Pallidus (GP). By contrast, cerebral metabolism in the amygdala nuclei (Basolateral, BLA; Central, CeA; Medial, MeA) was not significantly altered in WIN 55,212‐treated animals. | Data shown as the ¹⁴C‐2‐DG uptake ratio obtained for each RoI. *denotes p < 0.05 significant difference from control (unpaired Student's t‐test). Panel (b) – representative false colour autoradiograms at the level of the dorsal and ventral hippocampus showing altered cerebral metabolism in WIN 55,212‐2‐treated animals. Higher rates of metabolism are indicated by warmer colours (red/orange) and lower rates of metabolism by cooler colours (blue/green). Full data are shown in the Table S2.